Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer

ABSTRACT: This phase I/II trial studies the side effects and how well encorafenib, binimetinib, and nivolumab work in treating patients with microsatellite stable, BRAFV600E gene-mutated colorectal cancer that has spread to other places in the body (metastatic). Encorafenib and binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving encorafenib, binimetinib, and nivolumab may work better in treating patients with colorectal cancer compared to standard treatments.

DISEASE(S): Stage Iv Colon Cancer,Metastatic Colorectal Adenocarcinoma,Adenocarcinoma,Stage Iii Colon Cancer,Stage Iv Rectal Cancer,Stage Iv Colorectal Cancer,Stage Ivc Rectal Cancer,Stage Ivc Colorectal Cancer,Stage Iiia Rectal Cancer,Metastatic Colon Adenocarcinoma,Stage Iva Colorectal Cancer,Stage Iiia Colorectal Cancer,Stage Iva Rectal Cancer,Colon Cancer,Colorectal Neoplasms,Stage Ivb Colon Cancer,Stage Ivc Colon Cancer,Stage Iiib Colorectal Cancer,Stage Iii Colorectal Cancer,Metastatic Rectal Adenocarcinoma,Stage Iiib Rectal Cancer,Stage Iiib Colon Cancer,Stage Iiic Colon Cancer,Rectal Neoplasms,Stage Iii Rectal Cancer,Stage Iiic Rectal Cancer,Stage Ivb Rectal Cancer,Metastatic Microsatellite Stable Colorectal Carcinoma,Stage Ivb Colorectal Cancer,Stage Iiic Colorectal Cancer,Colonic Neoplasms,Stage Iva Colon Cancer,Stage Iiia Colon Cancer

PROVIDER: 2312809 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR